Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 1;22(3):1433.
doi: 10.3390/ijms22031433.

Mesenchymal Stem Cell-Derived Exosomes as New Remedy for the Treatment of Neurocognitive Disorders

Carl Randall Harrell  1 , Ana Volarevic  2 , Valentin Djonov  3 , Vladislav Volarevic  4
Affiliations
Review

Mesenchymal Stem Cell-Derived Exosomes as New Remedy for the Treatment of Neurocognitive Disorders

Carl Randall Harrell et al. Int J Mol Sci. .

Abstract

Mesenchymal stem cell (MSC)-derived exosomes (MSC-Exo) are nano-sized extracellular vesicles enriched with MSC-sourced neuroprotective and immunomodulatory microRNAs, neural growth factors, and anti-inflammatory cytokines, which attenuate neuro-inflammation, promote neo-vascularization, induce neurogenesis, and reduce apoptotic loss of neural cells. Accordingly, a large number of experimental studies demonstrated MSC-Exo-dependent improvement of cognitive impairment in experimental animals. In this review article, we summarized current knowledge about molecular and cellular mechanisms that were responsible for MSC-Exo-based restoration of cognitive function, emphasizing therapeutic potential of MSC-Exos in the treatment of neurocognitive disorders.

Keywords: exosomes; mesenchymal stem cells; neurocognitive disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram. The PRISMA flow diagram shows the flow of information through the different phases of article selection.
See this image and copyright information in PMC

References

    1. Lilamand M., Hourregue C., Paquet C. Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. Rev. Neurol. 2020;176:677–683. doi: 10.1016/j.neurol.2019.12.006. - DOI - PubMed
    1. Luck T., Then F.S., Schroeter M.L., Witte V., Engel C., Loeffler M., Thiery J., Villringer A., Riedel-Heller S.G. Prevalence of DSM-5 Mild Neurocognitive Disorder in Dementia-Free Older Adults: Results of the Population-Based LIFE-Adult-Study. Am. J. Geriatr. Psychiatry. 2017;25:328–339. doi: 10.1016/j.jagp.2016.07.001. - DOI - PubMed
    1. Subramaniyan S., Terrando N. Neuroinflammation and Perioperative Neurocognitive Disorders. Anes. Ana. 2019;128:781–788. doi: 10.1213/ANE.0000000000004053. - DOI - PMC - PubMed
    1. Appaix F., Nissou M.F., van der Sanden B., Dreyfus M., Berger F., Issartel J.P., Wion D. Brain mesenchymal stem cells: The other stem cells of the brain? World J. Stem. Cells. 2014;6:134–143. doi: 10.4252/wjsc.v6.i2.134. - DOI - PMC - PubMed
    1. Harrell C.R., Jovicic N., Djonov V., Arsenijevic N., Volarevic V. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells. 2019;8:1605. doi: 10.3390/cells8121605. - DOI - PMC - PubMed

MeSH terms